Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • IDWEEK 2026

Infectious Diseases Week (IDWeek) - Annual Meeting

October 21 - 24, 2026

  1. All
  2. AZD1200

HTML

Structure-based optimization of a bivalent vaccine against respiratory syncytial virus and human metapneumovirus

HTML

Outcomes of respiratory syncytial virus infection among adults with immunocompromising conditions: A systematic literature review

HTML

Healthcare resource utilization in adults with different comorbidities hospitalized with respiratory syncytial virus or human metapneumovirus in New York City, 2023-2024

HTML

Outcomes of respiratory viral coinfections in adults hospitalized with respiratory syncytial virus or human metapneumovirus in New York City, 2017-2024

HTML

Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among patients with comorbidities enrolled in the Acute Respiratory Illness in Adults (ARIA) study

HTML

Impact of acute respiratory illness due to human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) on health-related quality of life among adults treated in the outpatient setting: Results from the ARIA Study

HTML

Severe acute respiratory infections in hospitalized adults requiring respiratory support in Europe: A subgroup analysis of the id.DRIVE Study 2024-2025

HTML

Incidence of hospitalisation due to human metapneumovirus (hMPV) among adults with underlying comorbidities in Spain

HTML

Structure-based optimization of a bivalent vaccine against respiratory syncytial virus and human metapneumovirus

HTML

Outcomes of respiratory syncytial virus infection among adults with immunocompromising conditions: A systematic literature review

HTML

Healthcare resource utilization in adults with different comorbidities hospitalized with respiratory syncytial virus or human metapneumovirus in New York City, 2023-2024

HTML

Outcomes of respiratory viral coinfections in adults hospitalized with respiratory syncytial virus or human metapneumovirus in New York City, 2017-2024

HTML

Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among patients with comorbidities enrolled in the Acute Respiratory Illness in Adults (ARIA) study

HTML

Impact of acute respiratory illness due to human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) on health-related quality of life among adults treated in the outpatient setting: Results from the ARIA Study

HTML

Severe acute respiratory infections in hospitalized adults requiring respiratory support in Europe: A subgroup analysis of the id.DRIVE Study 2024-2025

HTML

Incidence of hospitalisation due to human metapneumovirus (hMPV) among adults with underlying comorbidities in Spain

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States